Nanoscope Therapeutics, a biotechnology company advancing disease-agnostic optogenetic therapies for retinal degenerations, announced a major global regulatory milestone with the U.S. FDA granting Regenerative Medicine Advanced Therapy (RMAT) designation for MCO-010 in Stargardt disease and the European Medicines Agency (EMA) awarding five Orphan designations spanning rod- and cone-dominant as well as macular dystrophies.
Science Significance
MCO-010 (sonpiretigene isteparvovec) is a one-time, in-office intravitreal optogenetic therapy designed to restore vision by reprogramming bipolar retinal cells into light-sensitive cells. Unlike many gene therapies, MCO-010 does not require genetic testing, surgical delivery, or repeat dosing, making it broadly applicable across heterogeneous retinal diseases. This platform represents a potentially transformative, disease-agnostic approach for millions affected by photoreceptor loss.
Regulatory Significance
The FDA RMAT designation, combined with prior Fast Track and Orphan Drug designations, underscores strong U.S. regulatory support for accelerating MCO-010’s path in Stargardt disease and retinitis pigmentosa. The five EMA Orphan designations expand European coverage to syndromic and non-syndromic rod- and cone-dominant dystrophies and macular dystrophies, positioning MCO-010 for expedited scientific advice, protocol assistance, and market exclusivity in the EU. Together, these milestones create parallel regulatory pathways across two of the world’s largest healthcare markets.
Business Significance
Advertisement
With both U.S. and European regulators validating MCO-010’s platform potential, Nanoscope strengthens its position as a global leader in ophthalmic innovation. The designations provide competitive advantages including reduced regulatory barriers, extended market protection, and enhanced investor confidence in late-stage development. These developments build on positive Phase 2b/3 RESTORE trial data in retinitis pigmentosa and STARLIGHT Phase 2 data in Stargardt disease, with pivotal Phase 3 trials expected to begin later this year.
Patients’ Significance
For patients with blinding retinal degenerations such as RP, SD, and macular dystrophies, treatment options remain severely limited. MCO-010 offers hope of restoring functional vision through a safe, outpatient procedure that does not depend on genetic subtype. This could allow patients who currently face inevitable progressive vision loss to regain independence and quality of life.
Policy Significance
The dual recognition by FDA and EMA highlights an evolving regulatory climate that is increasingly supportive of novel, gene-based and optogenetic therapies addressing rare diseases. It also reinforces the importance of cross-border regulatory harmonization in enabling faster global access to breakthrough treatments. By leveraging Orphan, Fast Track, and RMAT pathways, Nanoscope exemplifies how biotech firms can accelerate innovation while aligning with rare disease policy priorities in the U.S. and EU.
Transaction Highlights
The European Medicines Agency granted five Orphan designations for MCO-010 across syndromic and non-syndromic retinal dystrophies, including both rod- and cone-dominant forms and macular dystrophies. The U.S. Food and Drug Administration granted RMAT designation for Stargardt disease, adding to MCO-010’s existing Orphan Drug and Fast Track designations for both RP and SD. These recognitions validate the therapeutic potential of Nanoscope’s disease-agnostic optogenetic platform and provide regulatory and commercial advantages including accelerated development timelines, protocol assistance, and extended exclusivity. Clinical development momentum continues with a Phase 3 registrational trial in Stargardt disease and a Phase 2 trial in geographic atrophy expected to begin by year-end 2025.
Source: Nanoscope Therapeutic Press Release
